MedTrace Logo

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

NCT00003715 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 425

Last updated 2015-12-03

No results posted yet for this study

Summary

RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

BCG vaccine

BIOLOGICAL

autologous tumor cell vaccine

BIOLOGICAL

recombinant interferon alfa

DRUG

chemotherapy

DRUG

cyclophosphamide

Sponsors & Collaborators

  • AVAX Technologies

    lead INDUSTRY

Principal Investigators

  • Karen Doak · AVAX Technologies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003715 on ClinicalTrials.gov